Update on ascites and hepatorenal syndrome

Digestive and Liver Disease

Volumn 34, Issue 8, 2002, Pages 592-605

  Gentilini, P ^a,b   Vizzutti, F ^a   Gentilini, A ^a   Zipoli, M ^a   Foschi, M ^a   Romanelli, R G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Ascites; Hepatorenal syndorome; Hyperdynamic circulation; Liver cirrhosis

Indexed keywords

ALDOSTERONE ANTAGONIST; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE; ARGIPRESSIN; AUTACOID; CANRENOATE POTASSIUM; CANRENONE; DIURETIC AGENT; ENDOTHELIN; ENDOTOXIN; FUROSEMIDE; HUMAN ALBUMIN; KALLIKREIN; KININ; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OZAGREL; PLASMA SUBSTITUTE; SODIUM; SPIRONOLACTONE; TERLIPRESSIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; TORASEMIDE; UNINDEXED DRUG; VASODILATOR AGENT; WATER;

ADRENERGIC SYSTEM; ARTERIAL BLOOD; ASCITES; BLOOD VOLUME; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DATA ANALYSIS; DIGESTION; HEART OUTPUT; HEPATORENAL SYNDROME; HUMAN; HYDROSTATIC PRESSURE; IMPLANTATION; KIDNEY CLEARANCE; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PATHOGENESIS; PERITONEUM VEIN SHUNT; PLASMA VOLUME; PORTOSYSTEMIC ANASTOMOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM RETENTION; STENT; VASCULAR RESISTANCE; VASODILATATION; WATER RETENTION;

EID: 0036674291     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(02)80094-9     Document Type: Review

References (161)

1. Long course and prognostic factors of virus-induced cirrhosis of the liver
2. A 20-year prospective study of cirrhosis
3. Duration of survival in patients with Laennec's cirrhosis
4. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites
5. Survival and prognostic factors of cirrhotic patients with ascites: A study of 134 outpatients
6. Management of patients with cirrhosis and ascites
7. Prognostic factors in cirrhosis identified by Cox's regression model
8. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients
9. Prognostic significance of serum bile acids in cirrhosis
10. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics
11. Long-term prognosis and prognostic factors of liver cirrhosis in the 1980s
12. Prognostic evaluation of patients with parenchymal cirrhosis. Proposal of a new simple score
13. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites
14. Prognostic value of the renin-angiotensin system in response to salt restriction and prognosis of alcoholic ascitic cirrhosis
15. Renal failure in patients with cirrhosis of the liver. I. Clinical and pathologic characteristics
16. Haemodynamics and fluid retention in liver disease
17. Peripheral arteriolar vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis
18. The cardiac output at rest in Laennec's cirrhosis
19. Intrarenal distribution of plasma flow in cirrhosis as measured by transit renography: Relationship with plasma renin activity and sodium and water excreation
20. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis
21. The role of central blood volume in the development of sodium retention in portal hypertensive rats
22. Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis
23. Plasma volume in cirrhosis of the liver: Its relation to portal hypertension, ascites and renal failure
24. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in liver cirrhosis: The overflow theory of ascites formation
25. Pattern of sodium handling and its consequences in patients with preascitic cirrhosis
26. Osmoreception in the portal circulation
27. Osmosensitivity of the portal vein and vasopressin release in rats
28. Activation of the hypothalamo-neurohypophysial system by hypertonic superfusion of the rat mesentery
29. Effect of hepatic NaCl receptor stimulation on renal nerve activity in conscious rabbits
30. Afferent discharges from venous pressoreceptors in liver
31. Hepatorenal baroreflex in cirrhotic rats
32. Mechanisms of portal hypertension-induced alterations in renal hemodynamics, renal water excretion, and renin secretion
33. Serotoninergic hepatorenal reflex regulating renal glomerular depressor reflex regulating renal glomerular filtration rate
34. Hepatic vein, hepatic parenchymal, and inferior vena cava mechanoreceptors with phrenic afferent
35. Hepatorenal reflex regulating kidney function
36. Renal sympathetic nervous system in hepatic cirrhosis
37. Splachnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis
38. Effect of oral propranolol on circulating catecholamines in cirrhosis: Relationship to severity of liver disease and splanchnic haemodynamics
39. The effect of peritoneovenous shunting on catecholamine metabolism in patients with hepatic ascites
40. Sodium excretion in advanced cirrhosis: Effect of expansion of central blood volume and suppression of plasma aldosterone
41. A prognostic model for predicting survival in cirrhosis with ascites
42. Ascites, renal failure and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis and treatment
43. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites
44. Renin-angiotensin system in liver disease
45. Characterization of the renin-aldosterone system in decompensated cirrhosis
46. The renal and hemodynamic effects of the peritoneovenous shunt for intractable hepatic ascites
47. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites
48. Effect of angiotensin (AII) blockade with 1-Sar-8-Ala-All (saralasin) in patients with cirrhosis and ascites
49. Adverse effects of captopril in the treatment of resistant ascites, a state of functional bilateral artery stenosis
50. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver
51. Renal function, renal activity and endogenous vasoactive substance in cirrhosis
52. Metabolic clearance rates of arginine vasopressin in patients with cirrhosis
53. Role of vasopressin in abnormal water excretion in cirrhosis patients
54. Evidence that renal progtaglandins are involved in water metabolism in cirrhosis
55. Hyponatremia and arginine vasopressin secretion in patients with refractory hepatic ascites undergoing peritoneovenous shunting
56. Renal water handling in liver disease
57. Renal functional abnormalities in cirrhosis: Pathophysiology and management
58. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites
59. The significance of vasopressin as a pressor agent
60. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats
61. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats
62. Aquaretic effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention
63. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis
64. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites
65. Natriuretic hormone activity in the urine of cirrhotic patients
66. Plasma levels of brain natriuretic peptide in patients with cirrhosis
67. Atrial natriuretic peptide (ANP) in cirrhosis of the liver. Effect of the administration of ANP to cirrhotic patients
68. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention
69. Atrial natriuretic peptide and other natriuretic factors in cirrhosis
70. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites
71. Prostaglandins and related compounds
72. Altered renal and platelet arachidonic acid metabolism in cirrhosis
73. 2 in cirrhosis with ascites: Relationship to functional renal failure (hepatorenal syndrome)
74. 1 on renal function and plasma renin activity in alcoholic liver disease
75. Effect of sulindac and ibuprofen in patients with cirrhosis and ascites: An explanation for the renal-sparing effect of sulindac
76. Pathophysiology and treatment of ascites and the hepatorenal syndrome
77. 2 in the hepatorenal syndrome
78. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites
79. Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites
80. Vasoactive peptides and the kidney
81. Kallikreinbradykinin system in chronic alcoholic liver disease
82. Renal kallikrein excretion in cirrhotics with ascites: Relationship to renal hemodynamics
83. Regulatory function of the vascular endothelium
84. Biological actions and pathophysiologic significance of endothelin in the kidney
85. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome
86. Human urinary levels of 5,6-epoxy-eicosatrienoic acid are raised in disorders of salt and water handling
87. Endotoxin and renal dysfunction in liver disease
88. Endotoxemic acute renal failure in awake rats
89. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis
90. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis
91. Hemodynamic effects of glucagon in portal hypertension
92. Nitric oxide mediates in vitro hyporeactivity to vasopressor in mesenteric vessels of portal hypertensive rats
93. Nitric oxide: Physiology, pathophysiology and pharmacology
94. Hyperdynamic circulation in cirrhosis: A role for nitric oxide?
95. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats
96. In vitro hyporeactivity to methoxamine in portal hypertensive rats: Reversal by nitric oxide blockade
97. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition
98. Hyperdynamic circulation of advanced cirrhosis: A re-appraisal based by posture induced changes in hemodynamics
99. Nifedipine attenuates systemic and renal vasoconstriction during nitric oxide inhibition in humans
100. Human renal and systemic hemodynamics, natriuretic, and neorohumoral resposes to different doses of L-NAME
101. Effects of systemic NO synthesis inhibition on RPF, GFR, UNaV, and vasoactive hormones in healthy humans
102. Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: Reversal by L-arginine
103. Physiological role of nitric oxide in regulation of renal function in humans
104. Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans
105. Nitrix oxide synthesis inhibition does not impair water immersion-induced renal vasodilation in humans
106. The hepatic circulation in health and disease: Report of a single-topic symposium
107. Hemodynamic, renal and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis
108. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis
109. Alcoholic myopathy in heart and skeletal muscle
110. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis
111. Cirrhotic cardiomyopathy: Getting to the heart of the matter
112. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites
113. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis
114. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites
115. Hepatopulmonary syndrome associated with cardiorespiratory disease
116. Hepatopulmonary syndrome. Current concepts in diagnosis and therapeutic considerations
117. The hepatopulmonary syndrome
118. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome
119. Hepatopulmonary syndrome with progressive hypoxemia as an indicator for liver transplantation: Case reports and literature review
120. Hepatopulmonary syndrome in candidates for liver transplantation
121. The lung in patients with cirrhosis
122. Cerebral autoregulation in cirrhotic patients with ascites. A transcranial Doppler study
123. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis
124. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis
125. Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance
126. Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance
127. Extra-adrenal mineralcorticoids and cardiovascular tissue
128. Production of aldosterone in isolated rat blood vessels
129. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial
130. Alterations of the kidney in liver disease
131. Functional renal alterations in chronic liver diseases
132. Renal failure during liver disease. The significance of endotoxins
133. Acute tubular necrosis in hepatorenal syndrome: An electron microscopic study
134. Hypoxia of the renal medulla: Its implications for disease
135. Acute renal failure
136. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome. Experience in 300 patients
137. Effect of low sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis
138. Sodium retention in cirrhosis: Aspects of pathophysiology and treatment
139. Cardiovascular effects of cancenone in patients with preascitic cirrhosis
140. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system
141. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients
142. Comparison of the effects of torasemide and furosemide in nonazaotemic cirrhotic patients with ascites: A randomized, double-blind study
143. Clinical practice guidelines for the management of cirrhotic patients with ascites
144. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study
145. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of randomized study
146. Randomized comparative study of therapeutic paracentesis with the without intravenous albumin in cirrhosis
147. Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy
148. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites
149. A randomized prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites
150. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: A randomized controlled clinical trial comparing two diets with different sodium content
151. Management of adult patients with ascites caused by cirrhosis. AASLD Practice Guidelines
152. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites
153. Diuresis in the ascitic patients: A randomized controlled trial of three regimens
154. Diagnosis and treatment of hepatorenal syndrome
155. Effects of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
156. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis
157. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites
158. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
159. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome
160. Impact of pretransplant renal function on survival after liver transplantation
161. Ascites and hepatorenal syndrome during cirrhosis: Two entities or the continuation of the same complication?